NextFin News - A research team led by Justin Eyquem at the University of California, San Francisco, has successfully engineered cancer-fighting T cells directly within the living body, achieving a long-sought milestone in genetic medicine. According to a study published March 18 in Nature, the team utilized a combination of CRISPR-Cas9 and viral delivery systems to insert therapeutic genes into a precise location within the genome of mice. This site-specific integration at the TRAC locus not only mimics natural immune regulation but also eliminates the need for the costly, weeks-long laboratory manufacturing process that currently defines CAR T-cell therapy.
The breakthrough addresses the most significant bottleneck in modern immunotherapy: the "ex vivo" manufacturing cycle. Currently, patients must have their blood drawn, their T cells shipped to a specialized facility for genetic modification, and then wait for the cells to be expanded and returned. This process can cost upwards of $400,000 per patient and often takes too long for those with rapidly progressing late-stage cancers. By moving the entire engineering process into the patient’s own bloodstream via a simple injection, the UCSF team has effectively proposed a shift from a bespoke service to an "off-the-shelf" pharmaceutical product.
Precision is the hallmark of this new approach. Previous attempts at in vivo engineering relied on lentiviral vectors that integrated genes randomly into the DNA, a "shotgun" method that carries a non-negligible risk of causing secondary cancers if the gene lands in the wrong spot. The Eyquem team instead used Enveloped Delivery Vehicles (EDVs) to carry the CRISPR machinery and Adeno-Associated Virus (AAV6) to provide the genetic template. This dual-vehicle system ensures the Chimeric Antigen Receptor (CAR) is placed exactly where the T-cell receptor (TCR) usually sits. This site-specific placement allows the cell to regulate CAR expression using its own internal "volume knob," preventing the cellular exhaustion that often causes traditional CAR T therapies to fail over time.
The implications for the healthcare system are profound. Beyond the reduction in manufacturing costs, in vivo engineering could eliminate the need for "lymphodepletion"—the harsh chemotherapy used to clear out a patient’s existing immune system to make room for lab-grown cells. In the mouse models studied, the in vivo-generated cells were able to flourish and attack tumors without such pretreatment. This would significantly reduce the hospitalization time and the risk of life-threatening infections that currently accompany CAR T treatments.
However, the path to clinical adoption remains steep. While the study demonstrated efficacy in humanized mice, the human immune system is far more complex and prone to neutralizing the viral vectors used for delivery. The researchers noted that they had to optimize their AAV and EDV tools specifically to resist human antibodies, a challenge that will be the primary focus of upcoming Phase I trials. Furthermore, the efficiency of gene delivery must reach a therapeutic threshold; if too few T cells are converted in the body, the treatment will fail to outpace the cancer.
The commercial landscape for cell therapy is already reacting to these developments. Major pharmaceutical players, which have invested billions in centralized manufacturing hubs, may find their infrastructure disrupted by a technology that requires only a vial and a syringe. The success of this site-specific integration suggests that the next generation of genetic medicine will not be defined by how well we can grow cells in a lab, but by how precisely we can program them while they are still circulating in the patient’s veins.
Explore more exclusive insights at nextfin.ai.
